IL-12 (mouse):Fc (LALA-PG)-KIH (human) (rec.)

Interleukin-12 (IL-12) family members are heterodimer glycoproteins, composed of two covalently linked subunits, α and β chains. The α-subunit consists of IL-23p19, IL-27p28 and IL-12p35, and the β-subunit includes IL-12p40 and Epstein-Barr virus-induced gene (Ebi3). IL-12 members bind to cognate heterodimeric receptor chains expressed on T cells.

This family includes IL-12, IL-23, IL-27, IL-35 and IL-39. IL-12 and IL-23 are predominantly proinflammatory cytokines that contribute key roles in the development of Th1 and Th17 cells, respectively. IL-27 has both pro- and anti-inflammatory properties and is a potent T cell immunomodulator. IL-35, a new member of this family, is a potent inhibitory cytokine produced by natural, thymus-derived regulatory T cell (nTreg) populations. IL-39, the newest member of IL-12 family, mediates the inflammatory response through the activation of STAT1/STAT3 signaling pathway. These IL-12 family members link innate immunity with the development of adaptive immunity and are also important for regulating T cell responses.

IL-12 is composed of two subunits IL-12A/p35 and IL-12B/p40 and signals via a high-affinity IL-12R, leading to activation of STAT 4. IL-12 is produced by macrophages, dendritic cells and B cells. The key role of the pro-inflammatory IL-12 is to induce the IFN-γ which regulates the Th responses, to promote the naïve T cells to directly differentiate into effector cells (Th1) and then release IFN-γ. 

The protein IL-12 (mouse):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the IL-12A/p35:Fc (LALA-PG) Knobs sequence (synthesizing a protein of 60kDa) and one encoding for the IL12B/p40:Fc (LALA-PG) Holes sequence (synthesizing a protein of 75kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization and for secretion of the final protein IL-12 (mouse):Fc (LALA-PG)-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcγRs and C1q while FcRn binding and Fc stability remain unaffected.

InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.